1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 18, 2000
-----------------------
LA JOLLA PHARMACEUTICAL COMPANY
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Delaware 0-24274 33-0361285
- --------------------------------------------------------------------------------
(STATE OR OTHER JURISDICTION OF (COMMISSION (I.R.S. EMPLOYER
INCORPORATION) FILE NUMBER) IDENTIFICATION NO.)
6455 Nancy Ridge Drive San Diego, CA 92121
- --------------------------------------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (858) 452-6600
- --------------------------------------------------------------------------------
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
2
ITEM 5. OTHER EVENTS
On April 13, 2000, La Jolla Pharmaceutical Company (the
"Company") issued a press release announcing the Company's intent
to file a registration statement to register for resale the
underlying shares of Company common stock for the Company's
privately held warrants. The Company previously registered the
underlying shares for its publicly held warrants following its
initial public offering in 1994. The private and public warrants,
as well as an option granted to the underwriter of the Company's
initial public offering to purchase shares of Company common
stock and warrants, will expire on June 3, 2000. The Company's
Board of Directors does not plan to extend the expiration date.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
Pursuant to General Instruction F of Form 8-K, the following
document is incorporated by reference herein and attached as an
exhibit hereto:
EXHIBIT DESCRIPTION
------- -----------
99.1 La Jolla Pharmaceutical Company press release of
April 13, 2000.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
La Jolla Pharmaceutical Company
(Registrant)
Date: April 18, 2000 By: /s/ Steven B. Engle
-----------------------------------
(Signature)
Name: Steven B. Engle
Title: Chairman and Chief Executive
Officer
4
LA JOLLA PHARMACEUTICAL COMPANY
INDEX TO EXHIBITS
EXHIBIT
NUMBER EXHIBIT
- ------ -------
99.1 La Jolla Pharmaceutical Company press release of April 13, 2000.